Pharmaceutical Pricing and Reimbursement Information (PPRI) – New PPRI analysis including Spain

Vogler, Sabine; Espín, Jaime; Habl, Claudia

doi:10.3233/ppl-2009-0222

Cited by 34 publications

(70 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have examined the pharmaceutical reimbursement decision-making process in selected countries [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] or comparatively across a smaller number of selected countries [4,5,9,[32][33][34][35]. This review, to our knowledge, is the largest and most comprehensive contemporary examination that has been undertaken thus far.…”

Section: Discussionmentioning

confidence: 99%

A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries

et al. 2014

View full text Add to dashboard Cite

show abstract

“…There is a wealth of literature on policy options for pharmaceutical pricing and purchasing, but very little is focused on LMICs. Most research has been undertaken in Europe and the OECD countries (Jacobzone 2000;Productivity Commission 2001;Rietveld and Haaijer-Ruskamp 2002;Ess et al 2003;Mrazek and Mossialos 2004;GÖ G/Ö BIG 2006;Mossialos et al 2006;De Swaef and Antonissen 2007;Kovács et al 2007;Moïse and Docteur 2007a,b;Docteur 2007a,b, 2008;OECD 2008;Vogler et al 2008). Only a few studies have been conducted in LMICs (Gray and Matsebula 2000;Liu et al 2000;Zhen 2004;Meng et al 2005;Chen and Schweitzer 2008;Sengupta et al 2008;Sun et al 2008;Jirawattanapisal et al 2009;Thatte et al 2009).…”

Section: Policy Options For Pharmaceutical Pricing and Purchasingmentioning

confidence: 99%

“…A summary of medicine pricing, financing and public procurement in Western Pacific Region countries can be found at www.piemeds.com (WHO-WPRO 2009). Table 1 presents various pricing and purchasing strategies identified in this review, with examples of their use in LMICs. Pharmaceutical pricing and purchasing policies are regulations or procedures used by government authorities or coverage decision makers to determine or influence the prices that are paid for medicines (Vogler et al 2008). These policies can target manufacturers' prices, wholesale prices, retail prices or reimbursement prices.…”

Section: Policy Options For Pharmaceutical Pricing and Purchasingmentioning

confidence: 99%

Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries

Nguyen¹,

Knight²,

Roughead³

et al. 2014

Health Policy and Planning

View full text Add to dashboard Cite

Pharmaceutical expenditure is rising globally. Most high-income countries have exercised pricing or purchasing strategies to address this pressure. Low- and middle-income countries (LMICs), however, usually have less regulated pharmaceutical markets and often lack feasible pricing or purchasing strategies, notwithstanding their wish to effectively manage medicine budgets. In high-income countries, most medicines payments are made by the state or health insurance institutions. In LMICs, most pharmaceutical expenditure is out-of-pocket which creates a different dynamic for policy enforcement. The paucity of rigorous studies on the effectiveness of pharmaceutical pricing and purchasing strategies makes it especially difficult for policy makers in LMICs to decide on a course of action. This article reviews published articles on pharmaceutical pricing and purchasing policies. Many policy options for medicine pricing and purchasing have been found to work but they also have attendant risks. No one option is decisively preferred; rather a mix of options may be required based on country-specific context. Empirical studies in LMICs are lacking. However, risks from any one policy option can reasonably be argued to be greater in LMICs which often lack strong legal systems, purchasing and state institutions to underpin the healthcare system. Key factors are identified to assist LMICs improve their medicine pricing and purchasing systems.

show abstract

“…In Spain, the reference price system implementation in 2000 was facilitated by authorizing pharmacists to carry out generic substitution . Under the Ministerial Order SCO/2874/2007 adopted on September 28, 2007, some medicines demonstrating specific therapeutic or pharmacological characteristics can be explicitly excluded from substitution by pharmacists, unless express permission is granted by the prescribing physician .…”

Section: Introductionmentioning

confidence: 99%

Solution‐driven approaches to generic substitution challenges – a survey among international experts

Drozdowska

Hermanowski

2015

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The main objective of this study was to explore the perception and understanding of economic, legal, and social barriers that may restrain generic uptake among recognized international experts in health care, and to identify and verify recommendations on how to streamline generic substitution (GS) at no expense of therapeutic safety. A questionnaire survey was devised, and experts with world-renowned expertise in the field of generic medicinal products were selected. Almost 3/4 of respondents claimed that all drugs that satisfy bioequivalence criteria represent similar efficacy and adverse effects, and 1/4 of respondents believed that some differences could be reported. The majority of experts supported (i) the right of patients to refuse GS, (ii) the right of physicians to veto GS, and (iii) the introduction of a statutory obligation to provide patients with access to the cheapest generics available on the market. The main obstacles to more general uptake of generics were as follows: (i) perception of generics as lower quality products, (ii) absence of a transparent policy governing GS, and (iii) disincentives to pharmacists and physicians. Among the most popular recommendations were as follows: (i) introduction of various measures to aid physicians in generic prescribing, (ii) setting clear guidelines specifying when GS is not advisable, (iii) supporting competition on the generic market. The views of experts and the resulting recommendations were strongly affected by their opinion on the bioequivalence of generics. From this analysis, we have selected several principal recommendations which could help shape successful healthcare policies regarding GS.

show abstract

Pharmaceutical Pricing and Reimbursement Information (PPRI) – New PPRI analysis including Spain

Cited by 34 publications

References 0 publications

A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries

A Synthesis of Drug Reimbursement Decision-Making Processes in Organisation for Economic Co-operation and Development Countries

Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries

Solution‐driven approaches to generic substitution challenges – a survey among international experts

Contact Info

Product

Resources

About